[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633880":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":10,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":10,"enrollmentInfo":44,"targetDuration":47,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Label 1: Standard RRSO Group. Label 2: Individualized RS-DO Group. Label 3: Close Monitoring Group",null,"Description of Label 1: Participants undergoing concurrent bilateral salpingo-oophorectomy per guidelines. Description of Label 2: Participants undergoing salpingectomy with delayed oophorectomy to preserve hormones.Description of Label 3: Participants declining surgery and choosing regular ultrasound and CA-125 surveillance.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Associate Chief Physician\u002FAssociate Consultant, Doctor","CONTACT","18610689868","yuanli@bjmu.edu.cn",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Beijing","Beijing Municipality","100191","China","CN",{"type":27,"coordinates":28},"Point",[29,30],116.39723,39.9075,{"lat":30,"lon":29},[33],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100633880","a-bidirectional-cohort-study-on-prophylactic-resection-surgery-in-populations-at-moderate-to-high-risk-for-hereditary-ovarian-cancer-100633880",false,"NCT07532434","A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer","Inclusion Criteria:\n\n* Gender: Female. Age: 18 years or older at the time of enrollment.Genetic Risk: Documented carriers of pathogenic or likely pathogenic germline mutations in high-risk ovarian cancer susceptibility genes (including BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2). Data Availability: Willing to provide informed consent and allow access to clinical records, genetic testing reports, and follow-up data (bidirectional cohort). Psychosocial Status: Ability to complete quality of life and psychological assessment scales (e.g., GCS, SF-36, FSFI).\n\nExclusion Criteria:\n\n* Prior Malignancy: History of ovarian, fallopian tube, or primary peritoneal cancer prior to the baseline intervention. Synchronous Malignancy: Diagnosis of any other advanced-stage malignancy. Inability to Follow-up: Significant psychological, social, or geographical factors that would prevent regular long-term follow-up (3 years). Previous Extensive Pelvic Surgery: History of extensive pelvic surgery that precludes the feasibility of laparoscopic prophylactic salpingectomy or oophorectomy.","FEMALE","18 Years",{"count":45,"type":46},480,"ESTIMATED","15 Years","OBSERVATIONAL","The goal of this multi-center observational study is to learn about the effectiveness and safety of different prophylactic (preventive) surgical options in women at moderate-to-high genetic risk for hereditary ovarian cancer (HOC).\n\nThe main questions it aims to answer are:\n\nDoes individualized prophylactic surgery (such as removing fallopian tubes now and delaying ovary removal) effectively reduce the risk of developing ovarian cancer compared to standard care or close monitoring?\n\nHow do these different surgical interventions affect a woman's ovarian function and quality of life?\n\nWhat Participants Will Do:\n\nParticipants who are healthy carriers of specific genetic mutations (such as BRCA1\u002F2, RAD51C\u002FD, etc.) will be followed in a bidirectional cohort. Depending on the medical care and surgical path they choose with their doctors (Standard RRSO, Delayed Oophorectomy, or Close Monitoring), researchers will collect their clinical data, surgical pathology results, and follow-up information regarding cancer incidence and quality of life for 3 years.",[51,52],"Ovarian Cancer","Breast Cancer",[54,55,56,57,58],"Hereditary Ovarian Cancer (HOC)","BRCA1\u002F2 Mutation Carriers","Risk-Reducing Salpingo-Oophorectomy (RRSO)","Bidirectional Cohort Study","Risk-Reducing Salpingo-Oophorectomy（RRSO）","2026-04-08",{"date":61,"type":62},"2026-04-15","ACTUAL",{"date":64,"type":62},"2025-09-30",{"date":66,"type":46},"2035-09-30",{"name":5,"class":6},1]